Epstein‐Barr virus infection induces miR‐21 in terminally differentiated malignant B cells. Issue 6 (4th March 2015)

• Record Type: Journal Article
• Authors: Anastasiadou, Eleni; Garg, Neha; Bigi, Rachele; Yadav, Shivangi; Campese, Antonio Francesco; Lapenta, Caterina; Spada, Massimo; Cuomo, Laura; Botta, Annalisa; Belardelli, Filippo; Frati, Luigi; Ferretti, Elisabetta; Faggioni, Alberto; Trivedi, Pankaj
• Is Part Of: International journal of cancer. Volume 137:Issue 6(2015:Sep. 15)
• Page Start: 1491
• Page End: 1497
• Publication Date: 2015-03-04
• Subjects: Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.29489
• Languages: English
• ISSNs: 0020-7136

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>The association of Epstein‐Barr virus (EBV) with plasmacytoid malignancies is now well established but how the virus influences microRNA expression in such cells is not known. We have used multiple myeloma (MM) cell lines to address this issue and find that an oncomiR, miR‐21 is induced after <italic>in vitro</italic> EBV infection. The PU.1 binding site in miR‐21 promoter was essential for its activation by the virus. In accordance with its noted oncogenic functions, miR‐21 induction in EBV infected MM cells caused downregulation of p21 and an increase in cyclin D3 expression. EBV infected MM cells were highly tumorigenic in SCID mice. Given the importance of miR‐21 in plasmacytoid malignancies, our findings that EBV could further exacerbate the disease by inducing miR‐21 has interesting implications both in terms of diagnosis and future miR based therapeutical approaches for the virus associated plasmacytoid tumors.</p> </abstract>